Friday, June 02, 2017 12:39:18 PM
http://raps.org/regulatory-focus/news/2017/05/05/27488/FDA-proposal-explains-uses-for-new-innovation-funds/
FDA’s Center for Biologics Evaluation and Research (CBER) will also use innovation funds to facilitate a public process with the National Institute of Standards and Technology and other stakeholders to coordinate and prioritize the development of standards and consensus definitions of terms for new regenerative products. Meanwhile, use of FDA’s new Regenerative Medicine Advanced Therapy (RMAT) designation created under Cures has already begun. - See more at: http://raps.org/regulatory-focus/news/2017/05/05/27488/FDA-proposal-explains-uses-for-new-innovation-funds/#sthash.3Ts7nFHB.dpuf
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM